|
|
||||||||
From the Department of Pathology, New York University Medical Center, New York 10016
Abstract
Resistance to the BALB/c plasmacytoma MPC-11 by F1 hybrids between BALB/c and four C57BL/10 congenic resistant strains was abrogated or reduced by 450 rads total body irradiation but was unaffected by intravenous injection of 3 to 4 mg of silica. These results are consistent with the idea that hybrid resistance to MPC-11 depends on an active immune response and is different from Hh-1 controlled hybrid resistance.
Footnotes
1 This work was supported by American Cancer Society Grant VC-253 and, in part, by United States Public Health Service, National Institutes of Health Grants CA 20045 and CA 16247.
2 Recipient of Research Career Development Award AI 70653 from the National Institute of Allergy and Infectious Diseases.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |